News Image

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Provided By GlobeNewswire

Last update: Nov 20, 2025

– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels –   

Read more at globenewswire.com

HUMACYTE INC

NASDAQ:HUMA (12/5/2025, 8:26:34 PM)

After market: 1.23 0 (0%)

1.23

-0.07 (-5.38%)



Find more stocks in the Stock Screener

Follow ChartMill for more